Holen Sie sich die Stockscreener-App
4.72
1.46%
-0.07
Handel nachbörslich:
4.81
0.09
+1.91%
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo Therapeutics price target lowered to $15 from $20 at Chardan - TipRanks
Chart Analysts Warn of Resistance Near Lexeo Therapeutics Inc. PriceEntry Point & Free Accurate Trade Setup Notifications - sundaytimes.kr
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments - TipRanks
Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright - Investing.com
Lexeo Therapeutics Reports Q2 2025 Financial Results - TipRanks
Lexeo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Lexeo Reports Q2 Loss as Costs Jump 129% - sharewise.com
Lexeo Therapeutics: Can a Deep Pipeline and Regulatory Momentum Offset Earnings Woes? - AInvest
Lexeo Therapeutics Appoints New Chief Financial Officer - TipRanks
Lexeo Therapeutics appoints Louis Tamayo as CFO - MarketScreener
Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - Yahoo Finance
What makes Lexeo Therapeutics Inc. stock price move sharplyLow Float Short Squeeze Picks - thegnnews.com
Lexeo Therapeutics Inc. Matches Institutional Buying FilterBuy Low Sell High Stock Watch Strategy in Focus - beatles.ru
Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - MSN
Lexeo Therapeutics Inc. Stock Approaches Key Moving AverageChart Breakout Buy Signal Detection Confirmed - beatles.ru
Traders Watching For Reversal Pattern in Lexeo Therapeutics Inc.Reliable Alerts for Daily Stock Movers Released - metal.it
Oppenheimer Begins Coverage on Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
How does Lexeo Therapeutics Inc. generate profit in a changing economyBuild wealth with reliable stock picks - Jammu Links News
How strong is Lexeo Therapeutics Inc. company’s balance sheetGet real-time updates on market trends - Jammu Links News
What is Lexeo Therapeutics Inc. company’s growth strategyFree Risk Assessment Services - Jammu Links News
Is it the right time to buy Lexeo Therapeutics Inc. stockAchieve consistent profits with expert advice - Jammu Links News
How many analysts rate Lexeo Therapeutics Inc. as a “Buy”Superior returns - Jammu Links News
Published on: 2025-08-04 05:32:29 - Jammu Links News
What are the technical indicators suggesting about Lexeo Therapeutics Inc.Consistent double returns - Jammu Links News
What are Lexeo Therapeutics Inc. company’s key revenue driversPhenomenal returns - Jammu Links News
How does Lexeo Therapeutics Inc. compare to its industry peersMaximize your gains with professional insights - Jammu Links News
What is the risk reward ratio of investing in Lexeo Therapeutics Inc. stockMaximize gains with professional stock picks - Jammu Links News
Is Lexeo Therapeutics Inc. a good long term investmentMarket-beating performance - Jammu Links News
What are analysts’ price targets for Lexeo Therapeutics Inc. in the next 12 monthsBuild a portfolio with strong long-term growth - Jammu Links News
Published on: 2025-08-03 06:15:28 - Jammu Links News
What is the dividend policy of Lexeo Therapeutics Inc. stockDynamic profit opportunities - Jammu Links News
How volatile is Lexeo Therapeutics Inc. stock compared to the marketDiscover market opportunities with real-time data - Jammu Links News
Lexeo Therapeutics Analyst Begins Coverage on Bullish Note; Top 3 Initiations for Thursday - AInvest
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Lexeo Therapeutics(LXEO.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Lexeo Therapeutics Initiates Coverage: Oppenheimer Outperform Rating with $20 PT - AInvest
Lexeo Therapeutics shares rise 7.31% premarket after FDA grants breakthrough therapy designation to LX2006. - AInvest
Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating By Investing.com - Investing.com India
Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating - Investing.com Australia
Should I hold or sell Lexeo Therapeutics Inc. stock in 2025Advanced Screener Ideas For Fast Growth - Jammu Links News
Stifel Reiterates Buy Rating for Lexeo Therapeutics with $21 Price Target Following FDA Breakthrough Therapy Designation for LX2006 - AInvest
Candlestick Reversal Detected on Lexeo Therapeutics Inc.’s ChartPotential Breakout Stock List Published This Week - metal.it
Lexeo Therapeutics' LX2006 Receives Breakthrough Therapy Designation from FDA, Shares Rise 17% - AInvest
Lexeo Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowGrowth Based Stock Signal Screener Updated - metal.it
11 Best New Penny Stocks to Buy Right Now - Insider Monkey
What does LXEO's flat EPS in 2024 suggest for investors? - AInvest
How did LXEO's operating expenses trend in Q4 2024? - AInvest
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):